Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma
- PMID: 6705135
- DOI: 10.1007/BF00256542
Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma
Abstract
Melphalan absorption was studied over three consecutive days in five patients with multiple myeloma. On 1 day melphalan (approximately 7 mg/m2 = 10-12 mg) was administered IV, on 1 day PO fasting, and on 1 day PO after a standard breakfast. The order was different for each patient to minimise trends that might affect absorption. Melphalan concentrations were determined by high-pressure liquid chromatography and fitted to biexponential equations by computer. The parameters of these equations were in broad agreement with previously published data, and melphalan absorption varied between patients. Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml). There was a significant difference between the fraction of the dose of melphalan absorbed on the PO fed day (0.49 +/- 0.20) and on the PO fasting day (0.93 +/- 0.22), with P less than 0.005. This work suggests that melphalan should be taken first thing in the morning to obtain greatest absorption.
Similar articles
-
Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.Eur J Cancer Clin Oncol. 1982 Apr;18(4):355-62. doi: 10.1016/0277-5379(82)90006-2. Eur J Cancer Clin Oncol. 1982. PMID: 6889512
-
The effect of food on oral melphalan absorption.Cancer Chemother Pharmacol. 1986;16(2):194-7. doi: 10.1007/BF00256176. Cancer Chemother Pharmacol. 1986. PMID: 3948305
-
Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.Med Oncol Tumor Pharmacother. 1989;6(2):151-4. doi: 10.1007/BF02985238. Med Oncol Tumor Pharmacother. 1989. PMID: 2747308
-
The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.Eur J Clin Pharmacol. 1983;24(2):283-5. doi: 10.1007/BF00613833. Eur J Clin Pharmacol. 1983. PMID: 6840181 Clinical Trial.
-
Renal function in the elimination of oral melphalan in patients with multiple myeloma.Cancer Chemother Pharmacol. 1986;17(2):185-8. doi: 10.1007/BF00306752. Cancer Chemother Pharmacol. 1986. PMID: 3719900
Cited by
-
Interaction between cytostatics and nutrients.Med Oncol Tumor Pharmacother. 1991;8(2):79-86. doi: 10.1007/BF02988858. Med Oncol Tumor Pharmacother. 1991. PMID: 1749304 Review.
-
Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.Cancer Chemother Pharmacol. 1986;16(3):300-5. doi: 10.1007/BF00293997. Cancer Chemother Pharmacol. 1986. PMID: 3516430
-
The effect of dietary amino acids on the gastrointestinal absorption of melphalan and chlorambucil.Cancer Chemother Pharmacol. 1987;19(4):343-6. doi: 10.1007/BF00261486. Cancer Chemother Pharmacol. 1987. PMID: 3594717
-
Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.Cancer Chemother Pharmacol. 1988;21(1):1-8. doi: 10.1007/BF00262729. Cancer Chemother Pharmacol. 1988. PMID: 3342460
-
High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.Cancer Chemother Pharmacol. 1985;15(3):263-7. doi: 10.1007/BF00263898. Cancer Chemother Pharmacol. 1985. PMID: 4053270
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical